<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822536</url>
  </required_header>
  <id_info>
    <org_study_id>P071210</org_study_id>
    <nct_id>NCT00822536</nct_id>
  </id_info>
  <brief_title>Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation</brief_title>
  <acronym>OPTIDUAL</acronym>
  <official_title>Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare treatment with aspirin alone versus the combined antiplatelet treatment aspirin&#xD;
      and clopidogrel after 12 months of combined antiplatelet treatment following drug-eluting&#xD;
      stent (DES) implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-eluting stents (DES) substantially reduce restenosis compared with bare metal stents and&#xD;
      represent a significant advance in percutaneous coronary interventions (PCIs). Accordingly,&#xD;
      DES have been rapidly adopted into practice and are currently used in the majority of PCI&#xD;
      procedures. Despite their rapid acceptance, DES are not without limitations. In particular,&#xD;
      patients who receive DES (like those who receive conventional bare metal stents) remain at&#xD;
      risk of a 1% to 2% incidence of stent thrombosis, which is often associated with devastating&#xD;
      consequences like death or myocardial infarction. Understanding and eliminating mediators of&#xD;
      stent thrombosis are thus important goals for optimizing the clinical benefits of DES.&#xD;
      Delayed endothelial coverage after DES implantation has been demonstrated and is thought to&#xD;
      prolong the window of vulnerability to stent thrombosis. Consequently, current&#xD;
      recommendations for DES are: dual antiplatelet therapy for at least 12 months in patients at&#xD;
      low risk of bleeding, especially with &quot; off-label &quot; use. Because of rare but severe very late&#xD;
      stent thrombosis, the dual antiplatelet therapy is more and more prescribed in clinical&#xD;
      practice for several years.But it has been clearly demonstrated that the combination of&#xD;
      aspirin and clopidogrel (the thienopyridine the most used) significantly increase the rate of&#xD;
      severe and moderate bleedings when compared to aspirin alone. This is important if we&#xD;
      consider the possibility or the necessity to prolong the combined antiplatelet therapy after&#xD;
      stent implantation.ProposalTo compare treatment with aspirin alone versus the combined&#xD;
      antiplatelet treatment with aspirin and clopidogrel after 12 months of combined antiplatelet&#xD;
      treatment after DES implantation&#xD;
&#xD;
      NB : On the decision of the sponsor, the latest patient monitoring was advanced to September&#xD;
      30, 2014 instead of January 2015.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite criteria : death, non fatal myocardial infarction, non fatal stroke and severe bleeding</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non fatal myocardial infarction</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non fatal stroke</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (ARC définition)</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate bleeding (ISTH definition)</measure>
    <time_frame>At each visit (every 6 months) with Follow-up of 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1798</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bi therapy : aspirin/ clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy: aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and Clopidogrel</intervention_name>
    <description>Aspirin &lt;= 325 mg/j Clopidogrel = 75 mg /j</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aspirin: acid acetylsalycilic</other_name>
    <other_name>Clopidogrel: plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin : &lt;= 325 mg/j</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Aspirin: acid acetylsalycilic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion can be done either after stenting or 12 months later :&#xD;
&#xD;
        A: Patients admitted for DES implantation can be selected. After 12 months of bi therapy,&#xD;
        they will be randomized&#xD;
&#xD;
        B: patients who have got a DES implantation 12 months before can be selected and randomised&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Patients on aspirin and clopidogrel therapy at 12 months after DES implantation&#xD;
&#xD;
          -  Informed, written consent by the patient&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  DES in left main coronary artery&#xD;
&#xD;
          -  Oral anticoagulation therapy with coumadin derivatives&#xD;
&#xD;
          -  Active bleeding; bleeding diathesis; history intracranial bleeding&#xD;
&#xD;
          -  Known allergy or intolerance to the study medications: aspirin and clopidogrel&#xD;
&#xD;
          -  Pregnancy (present, suspected or planned) or positive pregnancy test (In women with&#xD;
             childbearing potential a negative pregnancy test is mandatory)&#xD;
&#xD;
          -  Patient's inability to fully comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gérard HELFT, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital la Pitié Salpêtrière Institut de Cardiologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

